Drugs / CART-HER-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01935843 | Sep 2013 → Sep 2016 | carcinoma, refractory malignant neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-HER-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01935843 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor-engineered T cell (CART) immunotherapy” PMID 28710747 ↗ Jul 2017 |
| Target | ERBB2 | “immunotherapy targeting human epidermal growth factor receptor 2 (HER2)” PMID 28710747 ↗ Jul 2017 |